185 related articles for article (PubMed ID: 19299008)
21. Helicobacter pylori eradication and gastric cancer: when is the horse out of the barn?
de Vries AC; Kuipers EJ; Rauws EA
Am J Gastroenterol; 2009 Jun; 104(6):1342-5. PubMed ID: 19491846
[TBL] [Abstract][Full Text] [Related]
22. Bacterial-binding chitosan microspheres for gastric infection treatment and prevention.
Gonçalves IC; Magalhães A; Fernandes M; Rodrigues IV; Reis CA; Martins MC
Acta Biomater; 2013 Dec; 9(12):9370-8. PubMed ID: 23920152
[TBL] [Abstract][Full Text] [Related]
23. In vitro and in vivo study of N-trimethyl chitosan nanoparticles for oral protein delivery.
Chen F; Zhang ZR; Yuan F; Qin X; Wang M; Huang Y
Int J Pharm; 2008 Feb; 349(1-2):226-33. PubMed ID: 17825506
[TBL] [Abstract][Full Text] [Related]
24. Effect of gastric environment on Helicobacter pylori adhesion to a mucoadhesive polymer.
Nogueira F; Gonçalves IC; Martins MC
Acta Biomater; 2013 Feb; 9(2):5208-15. PubMed ID: 22995406
[TBL] [Abstract][Full Text] [Related]
25. Lactoferrin and desferrioxamine are ineffective in the treatment of Helicobacter pylori infection and may enhance H. pylori growth and gastric inflammation in mice.
Huynh HQ; Campbell MA; Couper RT; Tran CD; Lawrence A; Butler RN
Lett Appl Microbiol; 2009 May; 48(5):517-22. PubMed ID: 19187488
[TBL] [Abstract][Full Text] [Related]
26. L-lactic acid secreted from gastric mucosal cells enhances growth of Helicobacter pylori.
Takahashi T; Matsumoto T; Nakamura M; Matsui H; Tsuchimoto K; Yamada H
Helicobacter; 2007 Oct; 12(5):532-40. PubMed ID: 17760722
[TBL] [Abstract][Full Text] [Related]
27. Helicobacter pylori infection induces genetic instability of nuclear and mitochondrial DNA in gastric cells.
Machado AM; Figueiredo C; Touati E; Máximo V; Sousa S; Michel V; Carneiro F; Nielsen FC; Seruca R; Rasmussen LJ
Clin Cancer Res; 2009 May; 15(9):2995-3002. PubMed ID: 19383819
[TBL] [Abstract][Full Text] [Related]
28. Early Helicobacter pylori eradication restores sonic hedgehog expression in the gastric mucosa of Mongolian gerbils.
Nishizawa T; Suzuki H; Nakagawa I; Minegishi Y; Masaoka T; Iwasaki E; Hibi T
Digestion; 2009; 79(2):99-108. PubMed ID: 19295210
[TBL] [Abstract][Full Text] [Related]
29. Presence of thrombin-activatable fibrinolysis inhibitor in Helicobacter pylori-associated gastroduodenal disease.
Ikeda A; Gabazza EC; Morser J; Imoto I; Kuroda M; D'Alessandro-Gabazza CN; Hara K; Ruiz DB; Bernabe PG; Katsurahara M; Toda M; Kobayashi Y; Yano Y; Sumida Y; Suzuki K; Taguchi O; Takei Y
Helicobacter; 2009 Apr; 14(2):147-55. PubMed ID: 19298343
[TBL] [Abstract][Full Text] [Related]
30. Biocompatible chitosan-DNAzyme nanoparticle exhibits enhanced biological activity.
Dass CR; Friedhuber AM; Khachigian LM; Dunstan DE; Choong PF
J Microencapsul; 2008 Sep; 25(6):421-5. PubMed ID: 18465314
[TBL] [Abstract][Full Text] [Related]
31. Release behavior of amoxicillin from glycol chitosan superporous hydrogels.
Park J; Kim D
J Biomater Sci Polym Ed; 2009; 20(5-6):853-62. PubMed ID: 19323894
[TBL] [Abstract][Full Text] [Related]
32. Preparation, characterization, and oral delivery of insulin loaded carboxylated chitosan grafted poly(methyl methacrylate) nanoparticles.
Cui F; Qian F; Zhao Z; Yin L; Tang C; Yin C
Biomacromolecules; 2009 May; 10(5):1253-8. PubMed ID: 19292439
[TBL] [Abstract][Full Text] [Related]
33. Polymeric nanoparticles of cholesterol-modified glycol chitosan for doxorubicin delivery: preparation and in-vitro and in-vivo characterization.
Yu JM; Li YJ; Qiu LY; Jin Y
J Pharm Pharmacol; 2009 Jun; 61(6):713-9. PubMed ID: 19505361
[TBL] [Abstract][Full Text] [Related]
34. A pH-Responsive Persistent Luminescence Nanozyme for Selective Imaging and Killing of
Yan LX; Wang BB; Zhao X; Chen LJ; Yan XP
ACS Appl Mater Interfaces; 2021 Dec; 13(51):60955-60965. PubMed ID: 34904434
[No Abstract] [Full Text] [Related]
35. Biocompatible nanoparticles trigger rapid bacteria clustering.
Larsen MU; Seward M; Tripathi A; Shapley NC
Biotechnol Prog; 2009; 25(4):1094-102. PubMed ID: 19565661
[TBL] [Abstract][Full Text] [Related]
36. Preparation of carboplatin-Fe@C-loaded chitosan nanoparticles and study on hyperthermia combined with pharmacotherapy for liver cancer.
Li FR; Yan WH; Guo YH; Qi H; Zhou HX
Int J Hyperthermia; 2009 Aug; 25(5):383-91. PubMed ID: 19391033
[TBL] [Abstract][Full Text] [Related]
37. Design and evaluation of novel pH-sensitive ureido-conjugated chitosan/TPP nanoparticles targeted to Helicobacter pylori.
Jing ZW; Jia YY; Wan N; Luo M; Huan ML; Kang TB; Zhou SY; Zhang BL
Biomaterials; 2016 Apr; 84():276-285. PubMed ID: 26851392
[TBL] [Abstract][Full Text] [Related]
38. [Genetic type of Helicobacter pylori and the efficacy of eradication therapy].
Parzecka M; Szaflarska-Popławska A; Mierzwa G; Gorzkiewicz M; Łuczak S; Grzybowski T
Pol Merkur Lekarski; 2009 Feb; 26(152):105-9. PubMed ID: 19388513
[TBL] [Abstract][Full Text] [Related]
39. Early Helicobacter pylori eradication decreases risk of gastric cancer in patients with peptic ulcer disease.
Wu CY; Kuo KN; Wu MS; Chen YJ; Wang CB; Lin JT
Gastroenterology; 2009 Nov; 137(5):1641-8.e1-2. PubMed ID: 19664631
[TBL] [Abstract][Full Text] [Related]
40. Stomach-specific anti-H. pylori therapy. I: Preparation and characterization of tetracyline-loaded chitosan microspheres.
Hejazi R; Amiji M
Int J Pharm; 2002 Mar; 235(1-2):87-94. PubMed ID: 11879743
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
